Search KLH Site
Find Articles by Tags
Addiction (18) Adjuvant - Alum (1) Adjuvant - GPI-0100 (1) Adjuvant - IL-4 (9) Adjuvant GM-CSF (16) Adjuvant KLH (4) Adjuvant Oil / Surfactant (4) Adjuvant QS-21 (25) Age & Physical Activity (3) Allergen-specific immunotherapy (1) Allergy – Pollen (2) Alzheimer's Disease (3) Antibody Response (35) Antibody Response IgA (14) Antibody Response IgE (6) Antibody Response IgG (106) Antibody Response IgM (71) Antibody Response IgY (1) APEC (1) Assay - Bioassay (2) Assay - Carbohydrate Microarray (1) Assay - ELISA (55) Assay - ELISPOT (7) Assay - Immunoassay (8) Assay - InVitro (18) Assay - InVivo (1) Atopic Dermatitis (1) Autoimmune Disease (1) B-epitope (1) Bone Marrow Transplant (6) Cancer (6) Cancer - Bladder (16) Cancer - Brain & CNS (8) Cancer - Breast (15) Cancer - Cervical (1) Cancer - Colorectal (10) Cancer - Esophageal (1) Cancer - Female Reproductive (7) Cancer - Leukemia (2) Cancer - Lung (4) Cancer - Lymphoma (25) Cancer - Melanoma (37) Cancer - Mesothelioma (1) Cancer - Myeloma (15) Cancer - Other (2) Cancer - Ovarian (3) Cancer - Pancreas (1) Cancer - Pediatric (3) Cancer - Peritoneal (2) Cancer - Prostate (9) Cancer - Renal (13) Cancer - Sarcoma (2) Clostridium difficile (5) Crohn's Disease (2) Cross-Reactive Antigens (6) Delayed-type hypersensitivity response (1) Dendritic Cell (66) Developmental (10) Diabetes (2) Disease Resistence (1) DNP-Ficoll (2) DTH (67) Environmental (15) Escherichia coli (1) Fingolimod (Gilenya) (1) Healthy Volunteers (18) HealthyAntibody Response - IgA (1) Hepatitis (2) HIV (11) HPV (3) Husbandry (3) Hypertension (1) id-KLH (29) IL 1 (4) IL 12 (2) IL 15 (1) IL 2 (10) IL 5 (1) IL 6 (1) IL 7 (1) Immune Disease - Autoimmune (13) Immune Disease - Primary (2) Immune Disease – Secondary (1) Immune Response - Cellular (187) Immune Response - Humoral (259) Immune Response Humoral (2) Immunotoxicity (37) Infection (1) Infectious Disease (5) Inflammatory Disease (1) Intradermal KLH (1) Kidney (1) KLH-BEC2 (1) KLH-BP16 (1) KLH-BPO (1) KLH-Conjugate (69) KLH-EGFR (2) KLH-FITC (1) KLH-Ganglioside (16) KLH-Globo H (7) KLH-GM2 (1) KLH-hD1 (1) KLH-HGP-30 (1) KLH-IL (1) KLH-Kinoid (8) KLH-Lewis Y (3) KLH-MUC (8) KLH-Oxycodone (2) KLH-sTn (9) KLH-TF (5) KLH-TN (3) Model - Canine (6) Model - Guinea Pig (10) Model - Livestock (10) Model - Mouse (73) Model - Other (32) Model - Primate (12) Model - Rat (51) Multiple Sclerosis (1) Nasal (3) Natrural Antibody (1) Neonatal (2) NK Cells (1) NSAID (1) Oral KLH (9) Oxycodone (3) Parasitic Disease (6) Pediatric (1) Plant-made (2) PLNA (1) Population Density (3) Psoriasis (1) Review Article (2) Rheumatoid Arthritis (11) Rituximab (Rituxan) (4) Russian thistle (1) Sal k 1 (1) Stress (8) Systemic Lupus Erythematosus (SLE) (7) TACA (2) TDAR (127) Therapeutics - KLH Alone (15) Transplant (6) Ultra Violet radiation (1) Uveitis (1) VEGF (3) Veterinary (1)
Terms and Privacy

KLH in Publications

Publications of scientific research involving KLH. Abstracts or full text articles are available by link to outside sites. If you know of a KLH-related publication that is not yet on KLH Site™, let us know.

(in order by date)

Entries in Cancer - Melanoma (37)


Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients

Florian Wimmers, Nienke de Haas, Anja Scholzen, Gerty Schreibelt, Elles Simonetti, Marc J. Eleveld, Huberdina M. L. M. Brouwers, Marjo Beldhuis-Valkis, Irma Joosten, Marien I. de Jonge, Winald R. Gerritsen, I. Jolanda M. de Vries, Dimitri A. Diavatopoulos, Joannes F. M. Jacobs.


Wimmers, F. et al. Monitoring of dynamic changes in Keyhole Limpet Hemocyanin(KLH)-specific B cells in KLH-vaccinated cancer patients. Sci. Rep. 7, 43486; doi: 10.1038/srep43486 (2017).




Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients

Steve Boudewijns, Harm Westdorp, Rutger H.T. Koornstra, Erik H.J.G. Aarntzen, Gerty Schreibelt, Jeroen H.A. Creemers, Cornelis J.A. Punt, Carl G. Figdor, I. Jolanda M. de Vries, Winald R. Gerritsen, and Kalijn F. Bol





Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

Kalijn F Bol,1,2 Carl G Figdor,1 Erik HJG Aarntzen,1,3 et al.

Oncoimmunology. 2015 Aug; 4(8): e1019197.
Published online 2015 Apr 1. doi:  10.1080/2162402X.2015.1019197


Relates to Clinical Trial NCT01530698.



Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial

Alexander M.M. EggermontStefan SuciuPiotr RutkowskiJeremy MarsdenMario SantinamiPhilippa CorrieSteinar AamdalPaolo A. AsciertoPoulam M. PatelWim H. KruitLars BastholtLorenzo BorgognoniMaria Grazia BernengoNeville DavidsonLarissa PoldersMichel Praet and Alan Spatz

JCO September 9, 2013JCO.2012.47.9303


Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells

Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt MW, Lesterhuis WJ, Van Riel M, Punt CJ, Adema GJ, Heerschap A, Figdor CG, Oyen WJ, de Vries IJ

Clin Cancer Res. 2013 Feb 4. [Epub ahead of print]


Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination

Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, Schadendorf D, Croockewit A, Blokx WA, Van Rossum MM, Kwok WW, Adema GJ, Punt CJ, Figdor CG.

Cancer Res. 2013 Jan 1;73(1):19-29. doi: 10.1158/0008-5472.CAN-12-1127. Epub 2012 Oct 18.


Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, Kiyohara Y, Yoshikawa S, Tanosaki R, Yamazaki N, Yamamoto A, Takesako K, Yamaguchi K, Akiyama Y

Oncol Rep. 2012 Oct;28(4):1131-8. doi: 10.3892/or.2012.1956. Epub 2012 Aug 7.


Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, Schuurhuis DH, Mus R, Thielemans K, de Vries IJ, Figdor CG, Punt CJ, Adema GJ

Clin Cancer Res. 2012 Oct 1;18(19):5460-5470. Epub 2012 Aug 15


Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters

Aarntzen EH, de Vries IJ, Göertz JH, Beldhuis-Valkis M, Brouwers HM, van de Rakt MW, van der Molen RG, Punt CJ, Adema GJ, Tacken PJ, Joosten I, Jacobs JF.

Cancer Immunol Immunother. 2012 Apr 21. [Epub ahead of print]


Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG

Clin Cancer Res. 2011 Sep 1;17(17):5725-35. Epub 2011 Jul 19


Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ

Cancer Immunol Immunother. 2011 Feb;60(2):249-60. Epub 2010 Nov 11


Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients 

Joannes F.M. Jacobs, Cornelis J.A. Punt1, W. Joost Lesterhuis, Roger P.M. Sutmuller, H. Mary-lène H. Brouwer, Nicole M. Scharenborg, Ina S. Klasen, Luuk B. Hilbrands, Carl G. Figdor, I. Jolanda M. de Vries, Gosse J. Adema

Clin Cancer Res October 15, 2010 16; 5067


Dendritic Cells Pulsed with Keyhole Limpet Hemocyanin and Cryopreserved Maintain Anti-Tumor Activity in a Murine Melanoma Model

Seagal Teitz Tennenbaum, Qiao Li, Mary A. Davis, and Alfred E. Chang.

Clin Immunol. 2008 December; 129(3): 482–491


Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.

Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ.

J Immunother. 2008 Jul-Aug;31(6):591-8.


Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.

Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.

Br J Haematol. 2007 Nov;139(3):415-24.

Full Text


Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after FcγRII-mediated uptake

Daniel Benitez-Ribas,1 Gosse J. Adema,1 Gregor Winkels,5 Ina S. Klasen,2 Cornelis J.A. Punt,3 Carl G. Figdor,1 and I. Jolanda M. de Vries

J Exp Med. 2006 July 10; 203(7): 1629–1635


Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.

Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK, Fay J.

J Immunother. 2005 Sep-Oct;28(5):505-16.


Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.

Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO

Clin Cancer Res. 2004 Jul 15;10(14):4717-23.


Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma

Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C, Lett M.

Cancer Immunol Immunother. 2004 Feb;53(2):125-34. Epub 2003 Nov 5.


Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.

de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ.

Clin Cancer Res. 2003 Nov 1;9(14):5091-100.